Parachichi(Avocado) linazuia kansa


Aug 2, 2016

  • Fat from avocados could combat acute myeloid leukaemia, AML
  • Fat targets leukaemia stem cells and stops them growing abnormally
  • Researchers say it could prolong life of leukaemia sufferers
  • AML is a deadly form of cancer that proves fatal within 5 years for 90 per cent of people over the age of 65
THEY are delicious in guacamole or cut up in salads, and we’ve long been told they’re a healthy form of fat.

But now, scientists believe avocados could help in the fight against cancer.

A new study has revealed fat from the creamy fruit can combat acute myeloid leukaemia (AML), a rare but deadly form of the disease.

Fat molecules from avocado tackles leukaemia stem cells, which are the root of the disease, as they grow into abnormal blood cells, Canadian researchers said.

Worldwide, there are few drugs that tackle leukaemia stem cells.


Professor Paul Spagnuolo from the University of Waterloo has discovered a lipid in avocados that combats acute myeloid leukemia by targeting the root of the disease – leukemia stem cells

In light of the findings, the researchers hope to create an avocado-derived drug they say could one day significantly increase life expectancy and quality of life for AML patients.

AML is a devastating disease and proves fatal within five years for 90 per cent of people over the age of 65.

In healthy people, stem cells in the bone marrow divide and grow to form fully developed mature red blood cells, platelets and white blood cells.

In patients with AML, this process goes awry.

Rather than forming into healthy red blood cells, many abnormal leukaemia cells are made.

These are immature cells that aren’t able to develop into normal functioning blood cells.

The researchers discovered the fat molecule from avocados, called avocatin B, is able to stop this process, targeting stem cells so healthy blood cells are able to grow.

The fat molecule from avocados tackles leukaemia stem cells, stopping them from growing abnormally. Pictured is a blood smear of AML under the microscope

Professor Paul Spagnuolo, from the University of Waterloo, said: ‘The stem cell is really the cell that drives the disease.

‘The stem cell is largely responsible for the disease developing and it’s the reason why so many patients with leukaemia relapse.

‘We’ve performed many rounds of testing to determine how this new drug works at a molecular level and confirmed that it targets stem cells selectively, leaving healthy cells unharmed.

‘Not only does avocatin B eliminate the source of AML, but its targeted, selective effects make it less toxic to the body, too.’

The drug is still years away from becoming approved for use in cancer clinics, but Professor Spagnuolo is already performing experiments to prepare the drug for a Phase I clinical trial.

This is the first round of trials where people diagnosed with AML could have access to the drug.

The research was published in the journal Cancer Research.

Source: DailyMail
Top Bottom